HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 机器翻译
🆙#ESMO26 快速口头报告 I：#LCSM 转移 🔥FLAURA2：一线（1L）奥希替尼（Osi）± 铂类–培美曲塞（Plat–Pem）治疗的EGFRm晚期NSCLC患者治疗期间血浆EGFRm动态及相关临床结局分析 🎙️ @dplanchard 🔢2719RO 🎯EGFRm清除率具有预后价值但无预测价值 🎯在第1、2、3、6周，无论清除状态如何，Osi+Plat–Pem相较于Osi单药的获益保持一致；两组清除率相当 ☑️NCT04035486 🔗 https://t.co/E2MIRGnkpb @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
热度 13 · 11 赞 · 0 回复 · 2 转发
会议摘要
NCT04035486NCT04035486按 - **标题 / Title：** A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) 对上
- **标题 / Title：** A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)读摘要原文 →来源：HHorinouchi · x.com